InsidersTradesSigma
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Explore the detailed record of transactions filed by KKR Genetic Disorder L.P.. Officer active across 1 company, notably BridgeBio Pharma, Inc.. In total, 3 disclosures have been published. Breakdown: 0 buy · 3 sells. Total volume traded: €505.8m. Activity tracked since 13 September 2024. The latest transaction was filed on 12 May 2025 (Cession). Regulator: SEC (Form 4). All data is accessible without signup.
3 of 3 declarations